{
  "abstract": "The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of primary progressive multiple sclerosis (PPMS) after allegations that the drug was approved despite internal concerns about its efficacy in women and a potential increased risk of breast cancer.",
  "authors": [
    {
      "affiliations": [
        "The BMJ"
      ],
      "name": "Peter Doshi"
    }
  ],
  "title": "Multiple sclerosis: Could Roche’s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?",
  "uid": "bcde6f4f-a911-5786-9dc3-d63b73cd3977"
}